Skip to content
OpenTrain AIFor AI Companies
← Back to explorer

Toward Closed-loop Molecular Discovery via Language Model, Property Alignment and Strategic Search

Junkai Ji, Zhangfan Yang, Dong Xu, Ruibin Bai, Jianqiang Li, Tingjun Hou, Zexuan Zhu · Dec 10, 2025 · Citations: 0

How to use this page

Provisional trust

This page is a lightweight research summary built from the abstract and metadata while deeper extraction catches up.

Best use

Background context only

What to verify

Read the full paper before copying any benchmark, metric, or protocol choices.

Evidence quality

Provisional

Derived from abstract and metadata only.

Abstract

Drug discovery is a time-consuming and expensive process, with traditional high-throughput and docking-based virtual screening hampered by low success rates and limited scalability. Recent advances in generative modelling, including autoregressive, diffusion, and flow-based approaches, have enabled de novo ligand design beyond the limits of enumerative screening. Yet these models often suffer from inadequate generalization, limited interpretability, and an overemphasis on binding affinity at the expense of key pharmacological properties, thereby restricting their translational utility. Here we present Trio, a molecular generation framework integrating fragment-based molecular language modeling, reinforcement learning, and Monte Carlo tree search, for effective and interpretable closed-loop targeted molecular design. Through the three key components, Trio enables context-aware fragment assembly, enforces physicochemical and synthetic feasibility, and guides a balanced search between the exploration of novel chemotypes and the exploitation of promising intermediates within protein binding pockets. Experimental results show that Trio reliably achieves chemically valid and pharmacologically enhanced ligands, outperforming state-of-the-art approaches with improved binding affinity (+7.85%), drug-likeness (+11.10%) and synthetic accessibility (+12.05%), while expanding molecular diversity more than fourfold. By combining generalization, plausibility, and interpretability, Trio establishes a closed-loop generative paradigm that redefines how chemical space can be navigated, offering a transformative foundation for the next era of AI-driven drug discovery.

Abstract-only analysis — low confidence

All signals on this page are inferred from the abstract only and may be inaccurate. Do not use this page as a primary protocol reference.

  • This page is still relying on abstract and metadata signals, not a fuller protocol read.

Should You Rely On This Paper?

Signal extraction is still processing. This page currently shows metadata-first guidance until structured protocol fields are ready.

Best use

Background context only

Use if you need

A provisional background reference while structured extraction finishes.

Main weakness

This page is still relying on abstract and metadata signals, not a fuller protocol read.

Trust level

Provisional

Usefulness score

Unavailable

Eval-fit score is unavailable until extraction completes.

Human Feedback Signal

Not explicit in abstract metadata

Evaluation Signal

Weak / implicit signal

Usefulness for eval research

Provisional (processing)

Extraction confidence 0%

What We Could Verify

These are the protocol signals we could actually recover from the available paper metadata. Use them to decide whether this paper is worth deeper reading.

Human Feedback Types

provisional (inferred)

None explicit

No explicit feedback protocol extracted.

"Drug discovery is a time-consuming and expensive process, with traditional high-throughput and docking-based virtual screening hampered by low success rates and limited scalability."

Evaluation Modes

provisional (inferred)

None explicit

Validate eval design from full paper text.

"Drug discovery is a time-consuming and expensive process, with traditional high-throughput and docking-based virtual screening hampered by low success rates and limited scalability."

Quality Controls

provisional (inferred)

Not reported

No explicit QC controls found.

"Drug discovery is a time-consuming and expensive process, with traditional high-throughput and docking-based virtual screening hampered by low success rates and limited scalability."

Benchmarks / Datasets

provisional (inferred)

Not extracted

No benchmark anchors detected.

"Drug discovery is a time-consuming and expensive process, with traditional high-throughput and docking-based virtual screening hampered by low success rates and limited scalability."

Reported Metrics

provisional (inferred)

Not extracted

No metric anchors detected.

"Drug discovery is a time-consuming and expensive process, with traditional high-throughput and docking-based virtual screening hampered by low success rates and limited scalability."

Rater Population

provisional (inferred)

Unknown

Rater source not explicitly reported.

"Drug discovery is a time-consuming and expensive process, with traditional high-throughput and docking-based virtual screening hampered by low success rates and limited scalability."

Human Feedback Details

This page is using abstract-level cues only right now. Treat the signals below as provisional.

  • Potential human-data signal: No explicit human-data keywords detected.
  • Potential benchmark anchors: No benchmark names detected in abstract.
  • Abstract highlights: 3 key sentence(s) extracted below.

Evaluation Details

Evaluation fields are inferred from the abstract only.

  • Potential evaluation modes: No explicit eval keywords detected.
  • Potential metric signals: No metric keywords detected.
  • Confidence: Provisional (metadata-only fallback).

Research Brief

Metadata summary

Drug discovery is a time-consuming and expensive process, with traditional high-throughput and docking-based virtual screening hampered by low success rates and limited scalability.

Based on abstract + metadata only. Check the source paper before making high-confidence protocol decisions.

Key Takeaways

  • Drug discovery is a time-consuming and expensive process, with traditional high-throughput and docking-based virtual screening hampered by low success rates and limited scalability.
  • Recent advances in generative modelling, including autoregressive, diffusion, and flow-based approaches, have enabled de novo ligand design beyond the limits of enumerative screening.
  • Yet these models often suffer from inadequate generalization, limited interpretability, and an overemphasis on binding affinity at the expense of key pharmacological properties, thereby restricting their translational utility.

Researcher Actions

  • Compare this paper against nearby papers in the same arXiv category before using it for protocol decisions.
  • Check the full text for explicit evaluation design choices (raters, protocol, and metrics).
  • Use related-paper links to find stronger protocol-specific references.

Caveats

  • Generated from abstract + metadata only; no PDF parsing.
  • Signals below are heuristic and may miss details reported outside the abstract.

Recommended Queries

Related Papers

Papers are ranked by protocol overlap, extraction signal alignment, and semantic proximity.

No related papers found for this item yet.